Subject(s)
Endoscopy , Peptic Ulcer/surgery , Anti-Ulcer Agents/therapeutic use , Cimetidine/therapeutic use , Follow-Up Studies , Furans/therapeutic use , Gastrectomy , Histamine H2 Antagonists/therapeutic use , Humans , Peptic Ulcer/diagnosis , Peptic Ulcer/drug therapy , Ranitidine , Sialoglycoproteins/therapeutic use , VagotomyABSTRACT
The Authors refer to their experience on 10 cases of benign cancer of the stomach studied either radiologically or endoscopically before the surgery intervention. Moreover the authors emphasize the importance of the association between the radiological investigation and the fibroscope in the determination of the benign characters of the gastric neoplasm and the possibility given by the endoscope to effect an extemporaneous biopsy in the cases of uncertain interpretation.
Subject(s)
Gastroscopy , Stomach Neoplasms/diagnosis , Adenoma/diagnosis , Adult , Cysts/diagnosis , Female , Humans , Leiomyoma/diagnosis , Lipoma/diagnosis , Male , Middle Aged , Radiography , Stomach/diagnostic imaging , Stomach Diseases/diagnosis , Stomach Neoplasms/pathologySubject(s)
Cimetidine/therapeutic use , Endoscopy , Gastrointestinal Hemorrhage/drug therapy , Guanidines/therapeutic use , Adult , Cimetidine/administration & dosage , Duodenal Ulcer/complications , Female , Gastrointestinal Hemorrhage/etiology , Humans , Male , Peptic Ulcer Hemorrhage/drug therapy , Stomach Diseases/complicationsABSTRACT
32 patients suffering from peptic ulcer have been selected. Of these 12 formed part of a previous series treated with cimetidine and subsequently relapsed; the other 20 were selected on the basis of endoscopic and functional examinations and were treated for the first time with cimetidine. The drug doses used were 1.2 g for 30 days and 0.3 g for a further 60 days. The purpose of the study was to check for possible recurrences by comparing the results obtained and their maintenance in the long term using these doses. 2 months after suspension of maintenance treatment there has not been any recurrence of the acute pain and dyspeptic symptomatology.
Subject(s)
Cimetidine/administration & dosage , Guanidines/administration & dosage , Peptic Ulcer/drug therapy , Adult , Aged , Ambulatory Care , Clinical Trials as Topic , Duodenal Ulcer/drug therapy , Female , Humans , Male , Middle Aged , Stomach Ulcer/drug therapySubject(s)
Cholelithiasis/diagnostic imaging , Cholesterol/metabolism , Adolescent , Adult , Aged , Bile Pigments/metabolism , Cholecystography , Cholelithiasis/metabolism , Female , Humans , Male , Middle AgedABSTRACT
A gastroscopic study was carried out in patients with rheumatic disorders to investigate the gastric tolerance of glucamethacin, a new, non-steroidal anti-inflammatory agent. The first stage was a double-blind crossover comparison of the effects of glucamethacin (420 mg/day) and indomethacin (100 mg/day), each given for 15 days in random order to 30 patients. In the second, open stage, 70 such patients, most of whom also had gastrointestinal pathology, received glucamethacin (420 mg/day) for 25 days. The results of endoscopic findings showed that significantly fewer (p less than 0.05) gastric lesions were produced after treatment with glucamethacin than after indomethacin. In the patients with gastro-duodenal pathology treated only with glucamethacin there was no change in endoscopy findings in 74% of the patients and only slight changes in the others.
Subject(s)
Anti-Inflammatory Agents/adverse effects , Gastrointestinal Diseases/chemically induced , Indomethacin/analogs & derivatives , Adolescent , Adult , Aged , Arthritis, Rheumatoid/drug therapy , Clinical Trials as Topic , Double-Blind Method , Endoscopy , Female , Gastric Mucosa/drug effects , Gastrointestinal Diseases/pathology , Gastroscopy , Glucosamine/adverse effects , Glucosamine/analogs & derivatives , Humans , Indomethacin/adverse effects , Male , Middle AgedABSTRACT
The gastric tolerance of parsalmide, a new analgesic, antirheumatic and sedative substance was tested on a group of 50 arthrorheumatic patients with the purpose of assessing gastric damage if any. It was also compared with the tolerance of the better known antitrheumatic drugs in current use. The study was conducted with the endoscopic method, parsalmide being administered in quantities of 600 mg/die per os, broken up into 3 doses, for a period of 20 days. Unlike phenylbutazone, indomethacin and cortisone, parsalmide showed no ulcerogenous effect nor haemorrhage type alterations at gastroduodenal level, at least in the cases treated. Furthermore, the slight surface oedematous gastropathies that appeared during the research were not important enough to demand suspension of the treatment. Endoscopically this picture can be judged of little clinical importance (as with the majority of well known analgesic-antirheumatic drugs) and its incidence came within the mean. A fair tranquillizing action, detectable in the particularly amenable behaviour of the subjects undergoing endoscopy, is also worth reporting.
